File this under food for thought. I hope this helps stimulate some good investment ideas.
clipped from blogs.wsj.com The drug industry’s about to plunge off a patent cliff, as blockbuster after blockbuster faces generic competition. But some companies are facing a steeper cliff than others. Evaluate Pharma, a data crunching outfit based in London, pooled consensus forecasts to estimate how things will look in 2014.
|
No comments:
Post a Comment